Oncology News

Consumption of unprocessed red or processed meat did not impact risk for colon cancer recurrence or mortality, according to a prospective cohort study of patients with stage III colon cancer published in JAMA Network Open.

Screening for hepatocellular carcinoma is critical in high-risk patients, according to a presentation at GUILD conference 2022.

The FDA granted orphan drug designation to CYNK-101, an investigational natural killer cell-based therapy for treatment of advanced HER2/neu-positive gastric or gastroesophageal junction adenocarcinoma.

The FDA has granted investigational device exemption to medical diagnostics company Check-Cap for a two-part pivotal study to evaluate C-Scan, a new screening test that detects precancerous polyps.

A culturally tailored patient navigation program improved colorectal cancer screening rates and reduced the gender gap in screenings among Hispanic patients, according to results published in Cancer.

The FDA granted orphan drug designation to CTB001, an investigational chimeric antigen receptor T-cell therapy for treatment of certain gastric cancers.

The FDA granted orphan drug designation to silmitasertib for treatment of biliary tract cancer.

The benefit of immune checkpoint inhibitor therapy for hepatocellular carcinoma did not vary by underlying liver disease, according to study results presented at ASCO Gastrointestinal Cancers Symposium.

Use of beta blockers did not affect outcomes among patients treated with immunotherapy for unresectable hepatocellular carcinoma, according to study results presented at ASCO Gastrointestinal Cancers Symposium.

A three-drug combination demonstrated activity for patients with microsatellite-stable, BRAF V600E-positive metastatic colorectal cancer, according to study results presented at ASCO Gastrointestinal Cancers Symposium.